Lab
Winchester Medical Center
Winchester Medical Center was paid $4.83M by Medicaid between Jan 2018 and Dec 2024, across 144 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 25% of everything it billed.
33Billing provider infoWINCHESTER MEDICAL CENTER
WINCHESTER, VA 22601
WINCHESTER, VA 22601
33aNPI1790024909assigned 02/07/2013
33bProvider typeClinical Medical Laboratory
28Total paid$4.83M
24GClaims475,618
24DCodes billed144
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Virginia
Rank by total paid#9 of 78
Median peer was paid$37K
This provider vs. median131×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CHAMBERS, JILL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 27,951 | $160K | |
| 2019 | 48,748 | $273K | |
| 2020 | 46,226 | $527K | |
| 2021 | 77,521 | $1.14M | |
| 2022 | 87,136 | $1.05M | |
| 2023 | 105,384 | $936K | |
| 2024incomplete | 82,652 | $744K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 25% | 21,655 | 20,245 | $1.20M |
| 80061 | Lipid panel | 5.3% | 30,833 | 28,534 | $254K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 5.0% | 14,819 | 13,548 | $242K |
| 80053 | Comprehensive metabolic panel | 4.2% | 36,124 | 32,918 | $202K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.0% | 7,431 | 6,938 | $191K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 3.8% | 7,410 | 6,927 | $184K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.8% | 23,754 | 21,848 | $182K |
| 80050 | General health panel | 3.4% | 8,001 | 7,566 | $162K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.0% | 4,210 | 3,057 | $145K |
| 81513 | 2.8% | 1,689 | 1,601 | $136K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.8% | 33,944 | 30,548 | $136K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.8% | 23,712 | 22,065 | $135K |
132 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.9% | 17,657 | $91K |
| 87081 | 1.9% | 18,384 | $91K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 859 | $84K |
| 36415 | Collection of venous blood by venipuncture | 1.7% | 53,803 | $83K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 1,291 | $74K |
| 82607 | 1.4% | 7,392 | $68K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.4% | 2,731 | $68K |
| 87481 | 1.2% | 2,064 | $60K | |
| 86803 | 1.2% | 6,055 | $60K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 1,523 | $60K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.1% | 3,167 | $54K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.1% | 2,267 | $53K |
| 82746 | <1% | 4,946 | $44K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,907 | $43K |
| 84466 | <1% | 5,890 | $42K | |
| 82728 | <1% | 4,907 | $42K | |
| 87186 | <1% | 7,522 | $42K | |
| 88142 | <1% | 3,085 | $38K | |
| 83970 | <1% | 1,631 | $38K | |
| 84439 | <1% | 6,532 | $36K | |
| 87070 | <1% | 4,948 | $31K | |
| 83540 | <1% | 6,053 | $25K | |
| 87077 | <1% | 4,770 | $25K | |
| 87522 | Neg quan hep c or qual rna | <1% | 838 | $18K |
| 86618 | <1% | 1,347 | $16K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 142 | $15K |
| 82043 | <1% | 4,890 | $14K | |
| 87340 | <1% | 2,000 | $14K | |
| 82570 | <1% | 4,136 | $13K | |
| 85027 | <1% | 3,199 | $13K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 666 | $12K |
| 80081 | <1% | 202 | $12K | |
| 81001 | <1% | 6,012 | $11K | |
| 86140 | <1% | 2,942 | $10K | |
| 87205 | <1% | 3,544 | $10K | |
| 87088 | <1% | 1,964 | $10K | |
| 83735 | <1% | 2,704 | $10K | |
| 80076 | <1% | 1,920 | $10K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 58 | $10K |
| 86038 | <1% | 1,156 | $10K | |
| 84481 | <1% | 1,001 | $9K | |
| 84153 | <1% | 730 | $8K | |
| 82105 | <1% | 758 | $8K | |
| 84403 | <1% | 369 | $7K | |
| 85610 | <1% | 2,684 | $7K | |
| 87799 | <1% | 109 | $7K | |
| 83880 | <1% | 312 | $7K | |
| 86003 | <1% | 182 | $7K | |
| 85652 | <1% | 3,249 | $6K | |
| 86592 | <1% | 1,965 | $6K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 746 | $6K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 361 | $5K |
| 86704 | <1% | 602 | $5K | |
| 83655 | <1% | 668 | $5K | |
| 84550 | <1% | 1,810 | $5K | |
| 80074 | <1% | 156 | $5K | |
| 82784 | <1% | 565 | $5K | |
| 87512 | <1% | 138 | $4K | |
| 86431 | <1% | 987 | $4K | |
| 87899 | <1% | 415 | $4K | |
| 84702 | <1% | 581 | $4K | |
| 86706 | <1% | 591 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 94 | $4K |
| 83690 | <1% | 755 | $4K | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 427 | $4K |
| 83001 | <1% | 222 | $3K | |
| 86376 | <1% | 307 | $3K | |
| 86787 | <1% | 342 | $3K | |
| 83516 | <1% | 303 | $3K | |
| 84146 | <1% | 185 | $3K | |
| 87147 | <1% | 690 | $3K | |
| 80069 | <1% | 549 | $3K | |
| 87493 | <1% | 105 | $3K | |
| 87902 | <1% | 15 | $2K | |
| 85007 | <1% | 1,097 | $2K | |
| 87046 | <1% | 397 | $2K | |
| 84460 | <1% | 2,831 | $2K | |
| 84156 | <1% | 878 | $2K | |
| 87660 | <1% | 126 | $2K | |
| 87480 | <1% | 125 | $2K | |
| 86708 | <1% | 224 | $2K | |
| 87510 | <1% | 126 | $2K | |
| 87045 | <1% | 390 | $1K | |
| 82248 | <1% | 636 | $1K | |
| 85018 | <1% | 823 | $1K | |
| 87420 | <1% | 121 | $1K | |
| 84703 | <1% | 235 | $1K | |
| 81003 | <1% | 782 | $1K | |
| 86480 | <1% | 76 | $1K | |
| 86430 | <1% | 224 | $1K | |
| 80164 | <1% | 134 | $992.54 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 57 | $953.88 |
| 86317 | <1% | 117 | $933.41 | |
| 83630 | <1% | 78 | $819.84 | |
| 84480 | <1% | 101 | $794.43 | |
| 82247 | <1% | 2,443 | $692.79 | |
| 84436 | <1% | 205 | $686.34 | |
| 87329 | <1% | 74 | $523.47 | |
| 86665 | <1% | 25 | $483.25 | |
| 87328 | <1% | 52 | $474.54 | |
| 82550 | <1% | 109 | $464.78 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 16 | $453.70 |
| 86200 | <1% | 46 | $443.65 | |
| 85730 | <1% | 135 | $442.91 | |
| 84100 | <1% | 150 | $362.73 | |
| 84075 | <1% | 2,326 | $355.69 | |
| 87184 | <1% | 69 | $348.50 | |
| 80055 | <1% | 18 | $312.00 | |
| 82785 | <1% | 30 | $311.36 | |
| 84450 | <1% | 2,325 | $309.06 | |
| 86800 | <1% | 26 | $307.54 | |
| 86039 | <1% | 40 | $299.20 | |
| 83021 | <1% | 29 | $279.63 | |
| 87177 | <1% | 76 | $274.05 | |
| 83615 | <1% | 101 | $270.53 | |
| 84402 | <1% | 12 | $260.30 | |
| 85014 | <1% | 170 | $232.92 | |
| 86705 | <1% | 33 | $226.52 | |
| 86664 | <1% | 24 | $225.84 | |
| 82040 | <1% | 2,288 | $212.89 | |
| 87338 | <1% | 26 | $197.40 | |
| 84155 | <1% | 2,321 | $172.34 | |
| 87301 | <1% | 18 | $152.46 | |
| 82103 | <1% | 13 | $117.10 | |
| 86900 | <1% | 46 | $108.51 | |
| 86901 | <1% | 46 | $108.51 | |
| 86709 | <1% | 13 | $75.66 | |
| 84479 | <1% | 15 | $69.81 | |
| 83525 | <1% | 13 | $66.32 | |
| 82977 | <1% | 15 | $59.46 | |
| 86703 | <1% | 20 | $55.11 | |
| 82150 | <1% | 13 | $47.43 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAMBERS, JILL (MGR INS CREDENTIALING)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.